Global Biopharmaceutical Fermentation Systems Industry

Global Biopharmaceutical Fermentation Systems Market to Reach $14. 8 Billion by 2027. Amid the COVID-19 crisis, the global market for Biopharmaceutical Fermentation Systems estimated at US$10.

New York, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biopharmaceutical Fermentation Systems Industry" - https://www.reportlinker.com/p05960813/?utm_source=GNW
9 Billion in the year 2020, is projected to reach a revised size of US$14.8 Billion by 2027, growing at aCAGR of 4.5% over the period 2020-2027. Upstream Products, one of the segments analyzed in the report, is projected to record 3.7% CAGR and reach US$5.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Downstream Products segment is readjusted to a revised 5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.2 Billion, While China is Forecast to Grow at 4.3% CAGR

The Biopharmaceutical Fermentation Systems market in the U.S. is estimated at US$3.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2027 trailing a CAGR of 4.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 3.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.We bring years of research experience to this 8th edition of our report. The 236-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

• Becton, Dickinson and Company

• Eppendorf AG

• F. Hoffmann-La Roche AG

• GE Healthcare

• Lonza Group AG

• Merck KgaA

• Nova Biomedical Corporation

• Sartorius Stedim Biotech SA

• Thermo Fisher Scientific, Inc.

Read the full report: https://www.reportlinker.com/p05960813/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Biopharmaceutical Fermentation Systems Competitor Market Share
Scenario Worldwide (in %): 2019 & 2025
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Biopharmaceutical
Fermentation Systems by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027

Table 2: World Historic Review for Biopharmaceutical
Fermentation Systems by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 3: World 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2012, 2020 &
2027

Table 4: World Current & Future Analysis for Upstream Products
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 5: World Historic Review for Upstream Products by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 6: World 15-Year Perspective for Upstream Products by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Downstream
Products by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 8: World Historic Review for Downstream Products by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 9: World 15-Year Perspective for Downstream Products by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Recombinant
Proteins by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 11: World Historic Review for Recombinant Proteins by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 12: World 15-Year Perspective for Recombinant Proteins by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Monoclonal
Antibodies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 14: World Historic Review for Monoclonal Antibodies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 15: World 15-Year Perspective for Monoclonal Antibodies
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Antibiotics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 17: World Historic Review for Antibiotics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 18: World 15-Year Perspective for Antibiotics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Probiotics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 20: World Historic Review for Probiotics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 21: World 15-Year Perspective for Probiotics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 23: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 24: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Biopharmaceutical
Companies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027

Table 26: World Historic Review for Biopharmaceutical Companies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 27: World 15-Year Perspective for Biopharmaceutical
Companies by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Contract
Manufacturing Organizations (CMOs) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027

Table 29: World Historic Review for Contract Manufacturing
Organizations (CMOs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 30: World 15-Year Perspective for Contract Manufacturing
Organizations (CMOs) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Contract Research
Organizations (CROs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027

Table 32: World Historic Review for Contract Research
Organizations (CROs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019

Table 33: World 15-Year Perspective for Contract Research
Organizations (CROs) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Academic and
Research Institutes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027

Table 35: World Historic Review for Academic and Research
Institutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019

Table 36: World 15-Year Perspective for Academic and Research
Institutes by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Food Industry by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 38: World Historic Review for Food Industry by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 39: World 15-Year Perspective for Food Industry by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027

Table 41: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019

Table 42: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Biopharmaceutical Fermentation Systems Market Share (in %)
by Company: 2019 & 2025
Market Analytics
Table 43: USA Current & Future Analysis for Biopharmaceutical
Fermentation Systems by Product - Upstream Products and
Downstream Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027

Table 44: USA Historic Review for Biopharmaceutical
Fermentation Systems by Product - Upstream Products and
Downstream Products Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 45: USA 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Product - Percentage Breakdown of Value
Sales for Upstream Products and Downstream Products for the
Years 2012, 2020 & 2027

Table 46: USA Current & Future Analysis for Biopharmaceutical
Fermentation Systems by Application - Recombinant Proteins,
Monoclonal Antibodies, Antibiotics, Probiotics and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 47: USA Historic Review for Biopharmaceutical
Fermentation Systems by Application - Recombinant Proteins,
Monoclonal Antibodies, Antibiotics, Probiotics and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 48: USA 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Application - Percentage Breakdown of
Value Sales for Recombinant Proteins, Monoclonal Antibodies,
Antibiotics, Probiotics and Other Applications for the Years
2012, 2020 & 2027

Table 49: USA Current & Future Analysis for Biopharmaceutical
Fermentation Systems by End-Use - Biopharmaceutical Companies,
Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs), Academic and Research Institutes, Food
Industry and Other End-Uses - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027

Table 50: USA Historic Review for Biopharmaceutical
Fermentation Systems by End-Use - Biopharmaceutical Companies,
Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs), Academic and Research Institutes, Food
Industry and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 51: USA 15-Year Perspective for Biopharmaceutical
Fermentation Systems by End-Use - Percentage Breakdown of Value
Sales for Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses for the Years 2012, 2020 & 2027

CANADA
Table 52: Canada Current & Future Analysis for
Biopharmaceutical Fermentation Systems by Product - Upstream
Products and Downstream Products - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 53: Canada Historic Review for Biopharmaceutical
Fermentation Systems by Product - Upstream Products and
Downstream Products Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 54: Canada 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Product - Percentage Breakdown of Value
Sales for Upstream Products and Downstream Products for the
Years 2012, 2020 & 2027

Table 55: Canada Current & Future Analysis for
Biopharmaceutical Fermentation Systems by Application -
Recombinant Proteins, Monoclonal Antibodies, Antibiotics,
Probiotics and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 56: Canada Historic Review for Biopharmaceutical
Fermentation Systems by Application - Recombinant Proteins,
Monoclonal Antibodies, Antibiotics, Probiotics and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 57: Canada 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Application - Percentage Breakdown of
Value Sales for Recombinant Proteins, Monoclonal Antibodies,
Antibiotics, Probiotics and Other Applications for the Years
2012, 2020 & 2027

Table 58: Canada Current & Future Analysis for
Biopharmaceutical Fermentation Systems by End-Use -
Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 59: Canada Historic Review for Biopharmaceutical
Fermentation Systems by End-Use - Biopharmaceutical Companies,
Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs), Academic and Research Institutes, Food
Industry and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 60: Canada 15-Year Perspective for Biopharmaceutical
Fermentation Systems by End-Use - Percentage Breakdown of Value
Sales for Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses for the Years 2012, 2020 & 2027

JAPAN
Table 61: Japan Current & Future Analysis for Biopharmaceutical
Fermentation Systems by Product - Upstream Products and
Downstream Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027

Table 62: Japan Historic Review for Biopharmaceutical
Fermentation Systems by Product - Upstream Products and
Downstream Products Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 63: Japan 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Product - Percentage Breakdown of Value
Sales for Upstream Products and Downstream Products for the
Years 2012, 2020 & 2027

Table 64: Japan Current & Future Analysis for Biopharmaceutical
Fermentation Systems by Application - Recombinant Proteins,
Monoclonal Antibodies, Antibiotics, Probiotics and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 65: Japan Historic Review for Biopharmaceutical
Fermentation Systems by Application - Recombinant Proteins,
Monoclonal Antibodies, Antibiotics, Probiotics and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 66: Japan 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Application - Percentage Breakdown of
Value Sales for Recombinant Proteins, Monoclonal Antibodies,
Antibiotics, Probiotics and Other Applications for the Years
2012, 2020 & 2027

Table 67: Japan Current & Future Analysis for Biopharmaceutical
Fermentation Systems by End-Use - Biopharmaceutical Companies,
Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs), Academic and Research Institutes, Food
Industry and Other End-Uses - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027

Table 68: Japan Historic Review for Biopharmaceutical
Fermentation Systems by End-Use - Biopharmaceutical Companies,
Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs), Academic and Research Institutes, Food
Industry and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 69: Japan 15-Year Perspective for Biopharmaceutical
Fermentation Systems by End-Use - Percentage Breakdown of Value
Sales for Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses for the Years 2012, 2020 & 2027

CHINA
Table 70: China Current & Future Analysis for Biopharmaceutical
Fermentation Systems by Product - Upstream Products and
Downstream Products - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027

Table 71: China Historic Review for Biopharmaceutical
Fermentation Systems by Product - Upstream Products and
Downstream Products Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 72: China 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Product - Percentage Breakdown of Value
Sales for Upstream Products and Downstream Products for the
Years 2012, 2020 & 2027

Table 73: China Current & Future Analysis for Biopharmaceutical
Fermentation Systems by Application - Recombinant Proteins,
Monoclonal Antibodies, Antibiotics, Probiotics and Other
Applications - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027

Table 74: China Historic Review for Biopharmaceutical
Fermentation Systems by Application - Recombinant Proteins,
Monoclonal Antibodies, Antibiotics, Probiotics and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 75: China 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Application - Percentage Breakdown of
Value Sales for Recombinant Proteins, Monoclonal Antibodies,
Antibiotics, Probiotics and Other Applications for the Years
2012, 2020 & 2027

Table 76: China Current & Future Analysis for Biopharmaceutical
Fermentation Systems by End-Use - Biopharmaceutical Companies,
Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs), Academic and Research Institutes, Food
Industry and Other End-Uses - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027

Table 77: China Historic Review for Biopharmaceutical
Fermentation Systems by End-Use - Biopharmaceutical Companies,
Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs), Academic and Research Institutes, Food
Industry and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 78: China 15-Year Perspective for Biopharmaceutical
Fermentation Systems by End-Use - Percentage Breakdown of Value
Sales for Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses for the Years 2012, 2020 & 2027

EUROPE
Market Facts & Figures
European Biopharmaceutical Fermentation Systems Market:
Competitor Market Share Scenario (in %) for 2019 & 2025
Market Analytics
Table 79: Europe Current & Future Analysis for
Biopharmaceutical Fermentation Systems by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027

Table 80: Europe Historic Review for Biopharmaceutical
Fermentation Systems by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 81: Europe 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK and
Rest of Europe Markets for Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for
Biopharmaceutical Fermentation Systems by Product - Upstream
Products and Downstream Products - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 83: Europe Historic Review for Biopharmaceutical
Fermentation Systems by Product - Upstream Products and
Downstream Products Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 84: Europe 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Product - Percentage Breakdown of Value
Sales for Upstream Products and Downstream Products for the
Years 2012, 2020 & 2027

Table 85: Europe Current & Future Analysis for
Biopharmaceutical Fermentation Systems by Application -
Recombinant Proteins, Monoclonal Antibodies, Antibiotics,
Probiotics and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 86: Europe Historic Review for Biopharmaceutical
Fermentation Systems by Application - Recombinant Proteins,
Monoclonal Antibodies, Antibiotics, Probiotics and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 87: Europe 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Application - Percentage Breakdown of
Value Sales for Recombinant Proteins, Monoclonal Antibodies,
Antibiotics, Probiotics and Other Applications for the Years
2012, 2020 & 2027

Table 88: Europe Current & Future Analysis for
Biopharmaceutical Fermentation Systems by End-Use -
Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 89: Europe Historic Review for Biopharmaceutical
Fermentation Systems by End-Use - Biopharmaceutical Companies,
Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs), Academic and Research Institutes, Food
Industry and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 90: Europe 15-Year Perspective for Biopharmaceutical
Fermentation Systems by End-Use - Percentage Breakdown of Value
Sales for Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses for the Years 2012, 2020 & 2027

FRANCE
Table 91: France Current & Future Analysis for
Biopharmaceutical Fermentation Systems by Product - Upstream
Products and Downstream Products - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 92: France Historic Review for Biopharmaceutical
Fermentation Systems by Product - Upstream Products and
Downstream Products Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 93: France 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Product - Percentage Breakdown of Value
Sales for Upstream Products and Downstream Products for the
Years 2012, 2020 & 2027

Table 94: France Current & Future Analysis for
Biopharmaceutical Fermentation Systems by Application -
Recombinant Proteins, Monoclonal Antibodies, Antibiotics,
Probiotics and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 95: France Historic Review for Biopharmaceutical
Fermentation Systems by Application - Recombinant Proteins,
Monoclonal Antibodies, Antibiotics, Probiotics and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 96: France 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Application - Percentage Breakdown of
Value Sales for Recombinant Proteins, Monoclonal Antibodies,
Antibiotics, Probiotics and Other Applications for the Years
2012, 2020 & 2027

Table 97: France Current & Future Analysis for
Biopharmaceutical Fermentation Systems by End-Use -
Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 98: France Historic Review for Biopharmaceutical
Fermentation Systems by End-Use - Biopharmaceutical Companies,
Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs), Academic and Research Institutes, Food
Industry and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 99: France 15-Year Perspective for Biopharmaceutical
Fermentation Systems by End-Use - Percentage Breakdown of Value
Sales for Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses for the Years 2012, 2020 & 2027

GERMANY
Table 100: Germany Current & Future Analysis for
Biopharmaceutical Fermentation Systems by Product - Upstream
Products and Downstream Products - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 101: Germany Historic Review for Biopharmaceutical
Fermentation Systems by Product - Upstream Products and
Downstream Products Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 102: Germany 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Product - Percentage Breakdown of Value
Sales for Upstream Products and Downstream Products for the
Years 2012, 2020 & 2027

Table 103: Germany Current & Future Analysis for
Biopharmaceutical Fermentation Systems by Application -
Recombinant Proteins, Monoclonal Antibodies, Antibiotics,
Probiotics and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 104: Germany Historic Review for Biopharmaceutical
Fermentation Systems by Application - Recombinant Proteins,
Monoclonal Antibodies, Antibiotics, Probiotics and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 105: Germany 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Application - Percentage Breakdown of
Value Sales for Recombinant Proteins, Monoclonal Antibodies,
Antibiotics, Probiotics and Other Applications for the Years
2012, 2020 & 2027

Table 106: Germany Current & Future Analysis for
Biopharmaceutical Fermentation Systems by End-Use -
Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 107: Germany Historic Review for Biopharmaceutical
Fermentation Systems by End-Use - Biopharmaceutical Companies,
Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs), Academic and Research Institutes, Food
Industry and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 108: Germany 15-Year Perspective for Biopharmaceutical
Fermentation Systems by End-Use - Percentage Breakdown of Value
Sales for Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses for the Years 2012, 2020 & 2027

ITALY
Table 109: Italy Current & Future Analysis for
Biopharmaceutical Fermentation Systems by Product - Upstream
Products and Downstream Products - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 110: Italy Historic Review for Biopharmaceutical
Fermentation Systems by Product - Upstream Products and
Downstream Products Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019

Table 111: Italy 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Product - Percentage Breakdown of Value
Sales for Upstream Products and Downstream Products for the
Years 2012, 2020 & 2027

Table 112: Italy Current & Future Analysis for
Biopharmaceutical Fermentation Systems by Application -
Recombinant Proteins, Monoclonal Antibodies, Antibiotics,
Probiotics and Other Applications - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027

Table 113: Italy Historic Review for Biopharmaceutical
Fermentation Systems by Application - Recombinant Proteins,
Monoclonal Antibodies, Antibiotics, Probiotics and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019

Table 114: Italy 15-Year Perspective for Biopharmaceutical
Fermentation Systems by Application - Percentage Breakdown of
Value Sales for Recombinant Proteins, Monoclonal Antibodies,
Antibiotics, Probiotics and Other Applications for the Years
2012, 2020 & 2027

Table 115: Italy Current & Future Analysis for
Biopharmaceutical Fermentation Systems by End-Use -
Biopharmaceutical Companies, Contract Manufacturing
Organizations (CMOs), Contract Research Organizations (CROs),
Academic and Research Institutes, Food Industry and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027

Table 116: Italy Historic Review for Biopharmaceutical
Fermentation Systems by End-Use - Biopharmaceutical Companies,
Contract Manufacturing Organizations (CMOs), Contract Research
Organizations (CROs), Academic and Research Institutes, Food
Industry and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019

Table 117: Italy 15-Year Perspective for Biopharmaceutical
Fermentation Systems by End-Use - Percentage Breakdown of Value

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05960813/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001